Finding the sweet spots of inhibition: Understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein

International Journal for Parasitology

Volumn 42, Issue 12, 2012, Pages 1055-1062

  Ntumngia, Francis B ^a   King, Christopher L ^b,c   Adams, John H ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malaria; Plasmodium vivax; Polymorphism; Vaccine

Indexed keywords

DUFFY BINDING PROTEIN; EPITOPE; MALARIA VACCINE;

ANTIBODY; IMMUNE RESPONSE; INHIBITION; MALARIA; PARASITE; POLYMORPHISM; PROTEIN; PROTOZOAN; VACCINE;

ANTIBODY RESPONSE; ANTIGEN BINDING; APICOMPLEXAN LIFE CYCLE STAGE; BIOASSAY; DRUG DESIGN; DRUG EFFECT; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; IMMUNE EVASION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BINDING SITES, ANTIBODY; EPITOPES; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; PLASMODIUM VIVAX; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE;

PLASMODIUM VIVAX;

EID: 84869868717     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.09.006     Document Type: Review

References (128)

1. Adams J.H., Blair P.L., Kaneko O., Peterson D.S. An expanding ebl family of Plasmodium falciparum. Trends Parasitol. 2001, 17:297-299.
2. Adams J.H., Hudson D.E., Torii M., Ward G.E., Wellems T.E., Aikawa M., Miller L.H. The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 1990, 63:141-153.
3. Adams J.H., Sim B.K., Dolan S.A., Fang X., Kaslow D.C., Miller L.H. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. USA 1992, 89:7085-7089.
4. Aikawa M., Miller L.H., Johnson J., Rabbege J. Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite. J. Cell Biol. 1978, 77:72-82.
5. Alexandre M.A., Ferreira C.O., Siqueira A.M., Magalhaes B.L., Mourao M.P., Lacerda M.V., Alecrim M.G. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg. Infect. Dis. 2010, 16:1611-1614.
6. Alves F.P., Durlacher R.R., Menezes M.J., Krieger H., Silva L.H., Camargo E.P. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am. J. Trop. Med. Hyg. 2002, 66:641-648.
7. Ampudia E., Patarroyo M.A., Patarroyo M.E., Murillo L.A. Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Mol. Biochem. Parasitol. 1996, 78:269-272.
8. Arevalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum. Vaccines 2010, 6:124-132.
9. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., Druilhe P., Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 2005, 73:8017-8026.
10. Baird J.K. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007, 23:533-539.
11. Barnwell J.W., Galinski M.R., DeSimone S.G., Perler F., Ingravallo P. Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp. Parasitol. 1999, 91:238-249.
12. Barnwell J.W., Nichols M.E., Rubinstein P. In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax. J. Exp. Med. 1989, 169:1795-1802.
13. Barouch D.H. HIV-1 vaccine candidate ineffective. AIDS Clin. Care 2007, 19:93.
14. Batchelor J.D., Zahm J.A., Tolia N.H. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat. Struct. Mol. Biol. 2011, 18:908-914.
15. Boyd M.F. A review of studies on immunity to vivax malaria. J. Nat. Mal. Soc. 1947, 6:12-31.
16. Casey J.L., Coley A.M., Anders R.F., Murphy V.J., Humberstone K.S., Thomas A.W., Foley M. Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes. Infect. Immun. 2004, 72:1126-1134.
17. Cattani J.A., Moir J.S., Gibson F.D., Ginny M., Paino J., Davidson W., Alpers M.P. Small-area variations in the epidemiology of malaria in Madang Province. Papua New Guinea Med. 1986, 29:11-17.
18. Cavasini C.E., Mattos L.C., Couto A.A., Bonini-Domingos C.R., Valencia S.H., Neiras W.C., Alves R.T., Rossit A.R., Castilho L., Machado R.L. Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception?. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1042-1044.
19. Ceravolo I.P., Sanchez B.A., Sousa T.N., Guerra B.M., Soares I.S., Braga E.M., McHenry A.M., Adams J.H., Brito C.F., Carvalho L.H. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin. Exp. Immunol. 2009, 156:502-510.
20. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Exp. Rev. Vaccines 2007, 6:381-390.
21. Chackerian B., Caldeira Jdo C., Peabody J., Peabody D.S. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. J. Mol. Biol. 2011, 409:225-237.
22. Chackerian B., Lowy D.R., Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 2001, 108:415-423.
23. Chitnis C.E. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr. Opin. Hematol. 2001, 8:85-91.
24. Chitnis C.E., Chaudhuri A., Horuk R., Pogo A.O., Miller L.H. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J. Exp. Med. 1996, 184:1531-1536.
25. Chitnis C.E., Miller L.H. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J. Exp. Med. 1994, 180:497-506.
26. Choe H., Moore M.J., Owens C.M., Wright P.L., Vasilieva N., Li W., Singh A.P., Shakri R., Chitnis C.E., Farzan M. Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol. Microbiol. 2005, 55:1413-1422.
27. Chootong P., Ntumngia F.B., VanBuskirk K.M., Xainli J., Cole-Tobian J.L., Campbell C.O., Fraser T.S., King C.L., Adams J.H. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 2010, 78:1089-1095.
28. Cole-Tobian J., King C.L. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol. Biochem. Parasitol. 2003, 127:121-132.
29. Cole-Tobian J.L., Cortes A., Baisor M., Kastens W., Xainli J., Bockarie M., Adams J.H., King C.L. Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J. Infect. Dis. 2002, 186:531-539.
30. Cole-Tobian J.L., Michon P., Biasor M., Richards J.S., Beeson J.G., Mueller I., King C.L. Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect. Immun. 2009, 77:4009-4017.
31. Coley A.M., Campanale N.V., Casey J.L., Hodder A.N., Crewther P.E., Anders R.F., Tilley L.M., Foley M. Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng. 2001, 14:691-698.
32. Collins W.E., Kaslow D.C., Sullivan J.S., Morris C.L., Galland G.G., Yang C., Saekhou A.M., Xiao L., Lal A.A. Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys. Am. J. Trop. Med. Hyg. 1999, 60:350-356.
33. Cowman A.F., Crabb B.S. Invasion of red blood cells by malaria parasites. Cell 2006, 124:755-766.
34. Crewther P.E., Matthew M.L., Flegg R.H., Anders R.F. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 1996, 64:3310-3317.
35. Duan J., Mu J., Thera M.A., Joy D., Kosakovsky Pond S.L., Diemert D., Long C., Zhou H., Miura K., Ouattara A., Dolo A., Doumbo O., Su X.Z., Miller L. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc. Natl. Acad. Sci. USA 2008, 105:7857-7862.
36. Dutta S., Ware L.A., Barbosa A., Ockenhouse C.F., Lanar D.E. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli. Infect. Immun. 2001, 69:5464-5470.
37. Dvorak J.A., Miller L.H., Whitehouse W.C., Shiroishi T. Invasion of erythrocytes by malaria merozoites. Science 1975, 187:748-750.
38. Fitch W.M., Leiter J.M., Li X.Q., Palese P. Positive Darwinian evolution in human influenza A viruses. Proc. Natl. Acad. Sci. USA 1991, 88:4270-4274.
39. Galinski M.R., Corredor-Medina C., Povoa M., Crosby J., Ingravallo P., Barnwell J.W. Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Mol. Biochem. Parasitol. 1999, 101:131-147.
40. Galinski M.R., Ingravallo P., Corredor-Medina C., Al-Khedery B., Povoa M., Barnwell J.W. Plasmodium vivax merozoite surface proteins-3beta and-3gamma share structural similarities with P. vivax merozoite surface protein-3alpha and define a new gene family. Mol. Biochem. Parasitol. 2001, 115:41-53.
41. Galinski M.R., Medina C.C., Ingravallo P., Barnwell J.W. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 1992, 69:1213-1226.
42. Galinski M.R., Xu M., Barnwell J.W. Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 235kDa rhoptry protein family. Mol. Biochem. Parasitol. 2000, 108:257-262.
43. Gaur D., Mayer D.C., Miller L.H. Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. Int. J. Parasitol. 2004, 34:1413-1429.
44. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., Rare L., Baisor M., Lorry K., Brown G.V., Pye D., Irving D.O., Smith T.A., Beck H.P., Alpers M.P. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 2002, 185:820-827.
45. Gilberger T.W., Thompson J.K., Triglia T., Good R.T., Duraisingh M.T., Cowman A.F. A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes. J. Biol. Chem. 2003, 278:14480-14486.
46. Grimberg B.T., Udomsangpetch R., Xainli J., McHenry A., Panichakul T., Sattabongkot J., Cui L., Bockarie M., Chitnis C., Adams J., Zimmerman P.A., King C.L. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 2007, 4:e337.
47. Guerra C.A., Howes R.E., Patil A.P., Gething P.W., Van Boeckel T.P., Temperley W.H., Kabaria C.W., Tatem A.J., Manh B.H., Elyazar I.R., Baird J.K., Snow R.W., Hay S.I. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Neg. Trop. Dis. 2010, 4:e774.
48. Hans D., Pattnaik P., Bhattacharyya A., Shakri A.R., Yazdani S.S., Sharma M., Choe H., Farzan M., Chitnis C.E. Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol. Microbiol. 2005, 55:1423-1434.
49. Harris I., Sharrock W.W., Bain L.M., Gray K.A., Bobogare A., Boaz L., Lilley K., Krause D., Vallely A., Johnson M.L., Gatton M.L., Shanks G.D., Cheng Q. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malaria J. 2010, 9:254.
50. Harris K.S., Casey J.L., Coley A.M., Masciantonio R., Sabo J.K., Keizer D.W., Lee E.F., McMahon A., Norton R.S., Anders R.F., Foley M. Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 2005, 73:6981-6989.
51. Hay S.I., Guerra C.A., Tatem A.J., Noor A.M., Snow R.W. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 2004, 4:327-336.
52. Haynes J.D., Dalton J.P., Klotz F.W., McGinniss M.H., Hadley T.J., Hudson D.E., Miller L.H. Receptor-like specificity of a Plasmodium knowlesi malarial protein that binds to Duffy antigen ligands on erythrocytes. J. Exp. Med. 1988, 167:1873-1881.
53. Healer J., Murphy V., Hodder A.N., Masciantonio R., Gemmill A.W., Anders R.F., Cowman A.F., Batchelor A. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol. Microbiol. 2004, 52:159-168.
54. Herrera S., Perlaza B.L., Bonelo A., Arevalo-Herrera M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int. J. Parasitol. 2002, 32:1625-1635.
55. Hodder A.N., Crewther P.E., Anders R.F. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 2001, 69:3286-3294.
56. Howes R.E., Patil A.P., Piel F.B., Nyangiri O.A., Kabaria C.W., Gething P.W., Zimmerman P.A., Barnadas C., Beall C.M., Gebremedhin A., Menard D., Williams T.N., Weatherall D.J., Hay S.I. The global distribution of the Duffy blood group. Nat. Commun. 2011, 2:266.
57. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., Long C.A., Miller L.H., Stowers A.W. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 2002, 70:6948-6960.
58. Ketema T., Bacha K., Birhanu T., Petros B. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malaria J. 2009, 8:177.
59. King C.L., Adams J.H., Xianli J., Grimberg B.T., McHenry A.M., Greenberg L.J., Siddiqui A., Howes R.E., da Silva-Nunes M., Ferreira M.U., Zimmerman P.A. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc. Natl. Acad. Sci. USA 2011, 108:20113-20118.
60. King C.L., Michon P., Shakri A.R., Marcotty A., Stanisic D., Zimmerman P.A., Cole-Tobian J.L., Mueller I., Chitnis C.E. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl. Acad. Sci. USA 2008, 105:8363-8368.
61. Kochar D.K., Das A., Kochar S.K., Saxena V., Sirohi P., Garg S., Kochar A., Khatri M.P., Gupta V. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am. J. Trop. Med. Hyg. 2009, 80:194-198.
62. Kocken C.H., Dubbeld M.A., Van Der Wel A., Pronk J.T., Waters A.P., Langermans J.A., Thomas A.W. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect. Immun. 1999, 67:43-49.
63. Kocken C.H., Withers-Martinez C., Dubbeld M.A., van der Wel A., Hackett F., Valderrama A., Blackman M.J., Thomas A.W. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 2002, 70:4471-4476.
64. Krotoski W.A., Collins W.E., Bray R.S., Garnham P.C., Cogswell F.B., Gwadz R.W., Killick-Kendrick R., Wolf R., Sinden R., Koontz L.C., Stanfill P.S. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 1982, 31:1291-1293.
65. Kusi K.A., Faber B.W., Riasat V., Thomas A.W., Kocken C.H., Remarque E.J. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS ONE 2010, 5:e15391.
66. Kusi K.A., Faber B.W., Thomas A.W., Remarque E.J. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 2009, 4:e8110.
67. Lacerda M.V., Mourao M.P., Alexandre M.A., Siqueira A.M., Magalhaes B.M., Martinez-Espinosa F.E., Filho F.S., Brasil P., Ventura A.M., Tada M.S., Couto V.S., Silva A.R., Silva R.S., Alecrim M.G. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malaria J. 2012, 11:12.
68. Lima-Junior J.C., Tran T.M., Meyer E.V., Singh B., De-Simone S.G., Santos F., Daniel-Ribeiro C.T., Moreno A., Barnwell J.W., Galinski M.R., Oliveira-Ferreira J. Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 2008, 26:6645-6654.
69. Lin E., Kiniboro B., Gray L., Dobbie S., Robinson L., Laumaea A., Schopflin S., Stanisic D., Betuela I., Blood-Zikursh M., Siba P., Felger I., Schofield L., Zimmerman P., Mueller I. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS ONE 2010, 5:e9047.
70. Marsh K., Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006, 28:51-60.
71. Mayer D.C., Kaneko O., Hudson-Taylor D.E., Reid M.E., Miller L.H. Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175. Proc. Natl. Acad. Sci. USA 2001, 98:5222-5227.
72. McHenry A.M., Barnes S.J., Ntumngia F.B., King C.L., Adams J.H. Determination of the molecular basis for a limited dimorphism, N417K, in the Plasmodium vivax Duffy-binding protein. PLoS ONE 2011, 6:e20192.
73. Menard D., Barnadas C., Bouchier C., Henry-Halldin C., Gray L.R., Ratsimbasoa A., Thonier V., Carod J.F., Domarle O., Colin Y., Bertrand O., Picot J., King C.L., Grimberg B.T., Mercereau-Puijalon O., Zimmerman P.A. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc. Natl. Acad. Sci. USA 2010, 107:5967-5971.
74. Mendes C., Dias F., Figueiredo J., Mora V.G., Cano J., de Sousa B., do Rosario V.E., Benito A., Berzosa P., Arez A.P. Duffy negative antigen is no longer a barrier to Plasmodium vivax - molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Neg. Trop. Dis. 2011, 5:e1192.
75. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001, 64:97-106.
76. Michon P., Cole-Tobian J.L., Dabod E., Schoepflin S., Igu J., Susapu M., Tarongka N., Zimmerman P.A., Reeder J.C., Beeson J.G., Schofield L., King C.L., Mueller I. The risk of malarial infections and disease in Papua New Guinean children. Am. J. Trop. Med. Hyg. 2007, 76:997-1008.
77. Michon P., Fraser T., Adams J.H. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect. Immun. 2000, 68:3164-3171.
78. Miller L.H., Mason S.J., Clyde D.F., McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. New Engl. J. Med. 1976, 295:302-304.
79. Miller L.H., Mason S.J., Dvorak J.A., McGinniss M.H., Rothman I.K. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 1975, 189:561-563.
80. Mohan K., Maithani M.M. Congenital malaria due to chloroquine-resistant Plasmodium vivax: a case report. J. Trop. Pediatr. 2010, 56:454-455.
81. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. USA 2003, 100:6753-6758.
82. Narum D.L., Fuhrmann S.R., Luu T., Sim B.K. A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol. Biochem. Parsitol. 2002, 119:159-168.
83. Ntumngia F.B., Adams J.H. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein. Clin. Vaccine Immunol. 2012, 19:30-36.
84. Ntumngia F.B., Schloegel J., Barnes S.J., McHenry A.M., Singh S., King C.L., Adams J.H. Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Infect. Immun. 2012, 80:1203-1208.
85. Polley S.D., Conway D.J. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 2001, 158:1505-1512.
86. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007, 77:79-87.
87. Ranjan A., Chitnis C.E. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc. Natl. Acad. Sci. USA 1999, 96:14067-14072.
88. Remarque E.J., Faber B.W., Kocken C.H., Thomas A.W. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 2008, 76:2660-2670.
89. Renia L., Ling I.T., Marussig M., Miltgen F., Holder A.A., Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect. Immun. 1997, 65:4419-4423.
90. Rijken M.J., Boel M.E., Russell B., Imwong M., Leimanis M.L., Pyae Phyo A., Muehlenbachs A., Lindegardh N., McGready R., Renia L., Snounou G., Singhasivanon P., Nosten F. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malaria J. 2011, 10:113.
91. Rogers W.O., Gowda K., Hoffman S.L. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine 1999, 17:3136-3144.
92. Russell B., Suwanarusk R., Borlon C., Costa F.T., Chu C.S., Rijken M.J., Sriprawat K., Warter L., Koh E.G., Malleret B., Colin Y., Bertrand O., Adams J.H., D'Alessandro U., Snounou G., Nosten F., Renia L. A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood 2011, 118:e74-81.
93. Ryan J.R., Stoute J.A., Amon J., Dunton R.F., Mtalib R., Koros J., Owour B., Luckhart S., Wirtz R.A., Barnwell J.W., Rosenberg R. Evidence for transmission of Plasmodium vivax among a Duffy antigen negative population in Western Kenya. Am. J. Trop. Med. Hyg. 2006, 75:575-581.
94. Sharma A., Khanduri U. How benign is benign tertian malaria?. J. Vector Borne Dis. 2009, 46:141-144.
95. Siddiqui A.A., Xainli J., Schloegel J., Carias L., Ntumngia F., Shoham M., Casey J.L., Foley M., Adams J.H., King C.L. Fine specificity of Plasmodium vivax duffy binding protein binding engagement of the duffy antigen on human erythrocytes. Infect. Immun. 2012, 80:2920-2928.
96. Sim B.K., Orlandi P.A., Haynes J.D., Klotz F.W., Carter J.M., Camus D., Zegans M.E., Chulay J.D. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J. Cell Biol. 1990, 111:1877-1884.
97. Singh A.P., Ozwara H., Kocken C.H., Puri S.K., Thomas A.W., Chitnis C.E. Targeted deletion of Plasmodium knowlesi duffy binding protein confirms its role in junction formation during invasion. Mol. Microbiol. 2005, 55:1925-1934.
98. Singh S., Pandey K., Chattopadhayay R., Yazdani S.S., Lynn A., Bharadwaj A., Ranjan A., Chitnis C. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. J. Biol. Chem. 2001, 276:17111-17116.
99. Singh S.K., Hora R., Belrhali H., Chitnis C.E., Sharma A. Structural basis for duffy recognition by the malaria parasite duffy-binding-like domain. Nature 2006, 439:741-744.
100. Singh S.K., Singh A.P., Pandey S., Yazdani S.S., Chitnis C.E., Sharma A. Definition of structural elements in Plasmodium vivax and P. knowlesi duffy-binding domains necessary for erythrocyte invasion. Biochem. J. 2003, 374:193-198.
101. Sirima S.B., Nebie I., Ouedraogo A., Tiono A.B., Konate A.T., Gansane A., Derme A.I., Diarra A., Ouedraogo A., Soulama I., Cuzzin-Ouattara N., Cousens S., Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007, 25:2723-2732.
102. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., Fouchier R.A. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305:371-376.
103. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
104. Soares I.S., Levitus G., Souza J.M., Del Portillo H.A., Rodrigues M.M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect. Immun. 1997, 65:1606-1614.
105. Storti-Melo L.M., Souza-Neiras W.C., Cassiano G.C., Taveira L.C., Cordeiro A.J., Couto V.S., Povoa M.M., Cunha M.G., Echeverry D.M., Rossit A.R., Arevalo-Herrera M., Herrera S., Machado R.L. Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil. Am. J. Trop. Med. Hyg. 2011, 84:58-63.
106. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Ouattara A., Kone A.K., Guindo A.B., Traore K., Traore I., Kouriba B., Diallo D.A., Diarra I., Daou M., Dolo A., Tolo Y., Sissoko M.S., Niangaly A., Sissoko M., Takala-Harrison S., Lyke K.E., Wu Y., Blackwelder W.C., Godeaux O., Vekemans J., Dubois M.C., Ballou W.R., Cohen J., Thompson D., Dube T., Soisson L., Diggs C.L., House B., Lanar D.E., Dutta S., Heppner D.G., Plowe C.V. A field trial to assess a blood-stage malaria vaccine. New Engl. J. Med. 2011, 365:1004-1013.
107. Tobin G.J., Trujillo J.D., Bushnell R.V., Lin G., Chaudhuri A.R., Long J., Barrera J., Pena L., Grubman M.J., Nara P.L. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008, 26:6189-6199.
108. Tran T.M., Moreno A., Yazdani S.S., Chitnis C.E., Barnwell J.W., Galinski M.R. Detection of a Plasmodium vivax erythrocyte binding protein by flow cytometry. Cytometry A 2005, 63:59-66.
109. Tsuboi T., Kappe S.H., Al-Yaman F., Prickett M.D., Alpers M., Adams J.H. Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein. Infect. Immun. 1994, 62:5581-5586.
110. Udomsangpetch R., Kaneko O., Chotivanich K., Sattabongkot J. Cultivation of Plasmodium vivax. Trends Parasitol. 2008, 24:85-88.
111. Valencia S.H., Rodriguez D.C., Acero D.L., Ocampo V., Arevalo-Herrera M. Platform for Plasmodium vivax vaccine discovery and development. Mem. Inst. Oswaldo Cruz 2011, 106(Suppl. 1):179-192.
112. VanBuskirk K.M., Cole-Tobian J.L., Baisor M., Sevova E.S., Bockarie M., King C.L., Adams J.H. Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies. J. Infect. Dis. 2004, 190:1556-1562.
113. VanBuskirk K.M., Sevova E., Adams J.H. Conserved residues in the Plasmodium vivax duffy-binding protein ligand domain are critical for erythrocyte receptor recognition. Proc. Natl. Acad. Sci. USA 2004, 101:15754-15759.
114. Vargas-Serrato E., Barnwell J.W., Ingravallo P., Perler F.B., Galinski M.R. Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol. Biochem. Parasitol. 2002, 120:41-52.
115. Verra F., Hughes A.L. Natural selection on apical membrane antigen-1 of Plasmodium falciparum. Parassitologia 1999, 41:93-95.
116. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
117. Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat. Rev. Microbiol. 2007, 5:555-563.
118. Wertheimer S.P., Barnwell J.W. Plasmodium vivax interaction with the human duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp. Parasitol. 1989, 69:340-350.
119. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 1990, 8:737-771.
120. Wilson-Adkins M., Adkins C. A new conjugate vaccine against pneumococcal disease. Nurse Pract. 2001, 26:52. 55-56, 59-62.
121. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
122. Wurtz N., Mint Lekweiry K., Bogreau H., Pradines B., Rogier C., Ould Mohamed Salem Boukhary A., Hafid J.E., Ould Ahmedou Salem M.S., Trape J.F., Basco L.K., Briolant S. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malaria J. 2011, 10:336.
123. Xainli J., Adams J.H., King C.L. The erythrocyte binding motif of Plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea. Mol. Biochem. Parasitol. 2000, 111:253-260.
124. Xainli J., Baisor M., Kastens W., Bockarie M., Adams J.H., King C.L. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J. Immunol. 2002, 169:3200-3207.
125. Xainli J., Cole-Tobian J.L., Baisor M., Kastens W., Bockarie M., Yazdani S.S., Chitnis C.E., Adams J.H., King C.L. Epitope-specific humoral immunity to Plasmodium vivax duffy binding protein. Infect. Immun. 2003, 71:2508-2515.
126. Yang C., Collins W.E., Sullivan J.S., Kaslow D.C., Xiao L., Lal A.A. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect. Immun. 1999, 67:342-349.
127. Yazdani S.S., Mukherjee P., Chauhan V.S., Chitnis C.E. Immune responses to asexual blood-stages of malaria parasites. Curr. Mol. Med. 2006, 6:187-203.
128. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.